|
|
| Product Name: | SR 202 | | Synonyms: | DIMETHYL (ALPHA-DIMETHOXYPHOSPHINYL-P-CHLOROBENZYL) PHOSPHATE;(4-CHLOROPHENYL)(DIMETHOXYPHOSPHINYL)METHYL PHOSPHORIC ACID DIMETHYL ESTER;SR 202;MIFOBATE;claniclor;phosphoricacid,(4-chlorophenyl)(dimethoxyphosphinyl)methyldimethylester;[(4-Chlorophenyl)(dimethoxyphosphinyl)methyl]dimethyl=phosphate;Clenicor | | CAS: | 76541-72-5 | | MF: | C11H17ClO7P2 | | MW: | 358.65 | | EINECS: | | | Product Categories: | Intracellular receptor | | Mol File: | 76541-72-5.mol |  |
| | SR 202 Chemical Properties |
| Boiling point | 436.6±45.0 °C(Predicted) | | density | 1.355±0.06 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO: 5 mg/mL | | form | crystalline | | color | white | | Water Solubility | Soluble to 100 mM in water |
| Safety Statements | 22-24/25 | | WGK Germany | 2 | | RTECS | TB8817000 |
| | SR 202 Usage And Synthesis |
| Description | SR 202 is an effective and specific PPARγ antagonist that selectively inhibits the transcriptional activity of PPARγ induced by TZD (IC50=140 μM). Sr-202 does not affect basal or ligand stimulated transcriptional activity of PPARα, PPARβ, or FXR. It has anti-obesity and anti-diabetes effects. | | Uses | Anti-atherosclerotic. | | Uses | SR 202 is a noniodinated, potential lipid-altering agent and an inhibitor of the peripheral conversion of T4 to T3 associated with thyroid hormone metabolism. | | Definition | ChEBI: Phosphoric acid [(4-chlorophenyl)-dimethoxyphosphorylmethyl] dimethyl ester is a trialkyl phosphate. | | Brand name | Clenicor (Symphar S.A.,Switzerland). | | Biological Activity | Selective PPAR γ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPAR γ transcriptional activity (IC 50 = 140 μ M) without affecting ligand-stimulated PPAR α , PPAR β or FXR transcriptional activity. Inhibits PPAR γ -dependent adipocyte differentiation and growth in vitro and in vivo . Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo . | | in vitro | sr-202 is a specific antagonist of ppar, which shows selectivity both among the ppar family members and other nuclear receptors. sr-202 also inhibits ppar-dependent differentiation of adipocytes. in cell culture, sr-202 efficiently antagonizes hormone- and tzd induced adipocyte differentiation [1]. | | in vivo | . decreasing ppar activity by treatment with sr-202 leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. treatment with sr-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice [1]. when wild-type mice are fed a high-fat diet, the plasma levels of tnf-α are raised, and sr-202 treatment protects against this rise [2].. | | IC 50 | 140 μm for attenuation of troglitazone-induced peroxisome proliferator-activated receptor gamma (ppar) transcriptional activity [1] | | storage | Desiccate at RT | | references | [1] rieusset j, touri f, michalik l, escher p, desvergne b, niesor e, wahli w. a new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. mol endocrinol. 2002 nov;16(11):2628-44.
[2] doggrell s. do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs expert opin investig drugs. 2003 apr;12(4):713-6. |
| | SR 202 Preparation Products And Raw materials |
|